Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465731 · ClinicalTrials.gov registry record · Phase 1
A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT07465731 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 62 participants.
The verdict
NCT07465731, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess relative bioavailability of centanafadine (CTN) SR tablet to CTN QD XR capsule in healthy adult participants.
Interventions
- DRUG Centanafadine SR
- DRUG Centanafadine QD XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-10-27 |
| Est. Completion | 2023-03-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465731
The ClinicalTrials.gov registry entry for NCT07465731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Centanafadine SR is the first listed.
NCT07465731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07465731 about?
NCT07465731 is a clinical study titled "A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine". The purpose of this trial is to assess relative bioavailability of centanafadine (CTN) SR tablet to CTN QD XR capsule in healthy adult participants.
What is the current status of trial NCT07465731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2022-10-27. Estimated completion is 2023-03-26.
What interventions are being tested in trial NCT07465731?
The interventions under investigation include: Centanafadine SR (DRUG), Centanafadine QD XR (DRUG).
Who is sponsoring clinical trial NCT07465731?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.